READ MORE "Sentinel at MedLab Middle East 2024: events agenda"
We are glad to announce that Sentinel Diagnostics (Sentinel CH. SpA), focused for 40 years on the development and production of in vitro diagnostic kits for clinical chemistry, immunochemistry, fecal testing, and molecular diagnostics, extends its expertise and activities in the field of chromatography and mass spectrometry through the acquisition of EUREKA S.r.l.- LAB DIVISION […]
READ MORE "Sentinel Diagnostics acquired Eureka srl Lab Division"
We are glad to announce the launch of new SENTiFIT®800, the first completely automated, high-throughput instrument for fecal tests. SENTiFIT®800 is particularly suitable for FIT screening programs and laboratories that process high volume of samples. It allows to: Satisfy high-throughput needs Reduce the operator hands-on time Increase the laboratory efficiency SENTiFIT®800 joins the range of […]
READ MORE "Sentinel Diagnostics launches the new SENTiFIT®800, a new completely automated and high-throughput instrument for fecal tests"Sentinel Diagnostics is at the 32nd ECCMID in Lisbon, Portugal. Come to join us at Booth 1-33.1 – On Sunday and Monday, visiting our stand, you would attend in-booth demonstrations about our: SENTiNAT® 200, the integrated system sample to result and SENTiNAT® X48, the automatic nucleic acids extraction and PCR setup system. To book your reservation: marketing@sentinel.it […]
READ MORE "ECCMID 2022, Lisbon – In-Booth Demonstrations"
After the postponement of EuroMedLab back in November 2021, we are happy to be present at EuroMedLab in Munich, Germany, on April 10th to 14th. Visiting us in Booth #205, Hall C1 you can: Learn more about our latest molecular diagnostic solutions and see how SENTiNAT®200, our new true sample-to-results system, can improve the laboratory […]
READ MORE "Sentinel Diagnostics at EuroMedLab Congress in Munich, Booth #205"
Sentinel Diagnostics is honored to announce its partnership with Mainz Biomed to support the ColoFuture clinical study, which evaluates the potential to integrate new mRNA biomarkers into ColoAlert, a detector for colorectal cancer (CRC). ColoAlert is a simple-to-administer test with a sensitivity and specificity nearly as high as the invasive colonoscopy. ColoFuture is an international […]
READ MORE "Sentinel Diagnostics is partner in the ColoFuture clinical study with Mainz Biomed and Alcedis GmbH"
Colorectal cancer (CRC) is the third most common cancer in men and women and has the second highest mortality rate worldwide. Several CRC cases are early identified thanks to the numerous screening programs in many countries but also many cases are found in patients presenting with symptoms in primary health care. The laboratory tests for […]
READ MORE "March is the National Colorectal Cancer Awareness Month"